Italian SME building simulation platforms for virtual clinical trials and regulatory-grade testing of medical devices and drugs.
InSilicoTrials develops computational simulation platforms for testing medical devices and drugs virtually — replacing or supplementing physical clinical trials with in-silico (computer-based) alternatives. Their technology enables pharmaceutical and medtech companies to simulate how cardiac devices, medicines, and other treatments perform in virtual patients, accelerating regulatory approval while reducing costs and animal testing. The company sits at the intersection of computational modelling, AI-driven healthcare, and regulatory science, providing tools that help bring medical innovations to market faster and more safely.
Core focus across ISW (lowering barriers to in-silico trial adoption), SimCardioTest (simulating cardiac devices/drugs for certification), and Disc4All (computational simulations in translational medicine).
SimCardioTest — their largest funded project (EUR 969K) — focuses specifically on simulation-based testing and certification of cardiac devices and medicines.
BRAINTEASER applies AI and decision support systems for personalized home care of ALS and multiple sclerosis patients.
Both ISW and SimCardioTest explicitly address regulatory approval pathways for simulation-validated medical products.
Disc4All involved multiscale modelling, bioinformatics, and mechanobiology applied to intervertebral disc research.
InSilicoTrials entered H2020 in 2020 with foundational computational biology work — multiscale modelling, bioinformatics, and virtual physiological human research (Disc4All, ISW). By 2021, their focus shifted decisively toward applied clinical impact: AI-driven personalized healthcare, wearable-based risk detection, regulatory approval for medical devices, and real-world patient care at home (BRAINTEASER, SimCardioTest). The trajectory shows a clear move from building simulation infrastructure to deploying it for direct clinical and regulatory use cases.
InSilicoTrials is moving toward becoming a go-to platform for regulatory-grade virtual testing of medical devices and drugs, with increasing AI integration for personalized medicine.
InSilicoTrials operates exclusively as a project participant, never as coordinator — typical for a technology SME that brings specialized simulation capabilities into larger research consortia. With 44 unique partners across 17 countries in just 4 projects, they work in large, diverse consortia and appear comfortable integrating their platform into multi-partner efforts. This makes them an accessible, low-friction partner: they bring deep technical expertise without needing to lead.
Despite only 4 projects, InSilicoTrials has built a broad network of 44 partners across 17 countries, indicating they consistently join large international consortia. Their reach spans most of the EU with no narrow geographic bias.
InSilicoTrials occupies a rare niche: a private company whose core business IS in-silico trials — not a university lab exploring the concept, but a company building commercial simulation platforms for regulatory use. Their combination of computational modelling expertise with direct regulatory science focus makes them uniquely positioned to help medical device and pharma companies navigate the emerging regulatory acceptance of virtual evidence. For consortium builders, they offer a ready-made industry partner that bridges the gap between academic simulation research and real-world regulatory approval.
